Whole Genome Amplification Services
Important factors about input genomic DNA
- Human, animal, plant, or microbial DNA amplify with same efficiency
- WGA amplification is independent of methylation status of DNA
- Molecular weight should be more than 200 bases
- DNA can be in solution, formalin-fixed paraffin sections, or ethanol-fixed
- DNA can be isolated using any of the standard methods or kits
- DNA can be single-stranded or double-stranded
- For most robust performance input should be at least 50 ng of DNA at a concentration of >5 ng/uL in TE
Important features of WGA amplified DNA
- Average molecular weight ~ 500 b
- Natural base composition
- dsDNA with variable amount of ssDNA
- Virtually no background (negative controls show no DNA amplification)
- WGA produces from 10 ug to 10 mg of amplified product
- Uniform concentration of ~100 ng/uL
- Virtually free of dNTPs and oligonucleotide primers
- Nuclease-free
- PCR inhibitor free
- Stable at -20*C
- Proofreading available on request
Example project specifications
- Normally more than twenty and less than ten thousand samples are grouped into a project.
- Input DNA—50 ng at > 5 ng/uL in TE or water, 96-well format with 4 unused control wells
- Output DNA—Multiples of 10 ug at >100 ng/uL in TE, purified by Millipore Montage, 96-well format
- Input and output DNA is subject to QC procedures so that the customer receives a uniform product quality and concentration, regardless of the condition of the starting material, which eliminates critical variables for sequencing and genotyping. If input QC criteria of DNA quantity and concentration are met, Rubicon guarantees amplification to a specific amount of PCR-amplifiable DNA.
- Turn-around—Normally 2 - 10 weeks, subject to production schedule
- Quantity discounts available
Value-added services
- Extraction of DNA from blood, serum, plasma, buccal swabs, FTA/IsoCode/Guthrie cards
- Preparation of array-ready labeled WGA DNA as 25 – 100 b fragments with biotin or fluorescent labels.
- Custom amplification with “GC-boost” reagents to normalize amplification of extremely GC-rich sequences.
- Proofreading available on request.
- Manufacture of amplified DNA for microarray fabrication and FISH probe synthesis
- Contract genomics services
Project flow
Think about your requirements, such as:
- Number and type of samples
- Amount of DNA required (input and output)
- Importance of specific quality control measures
- Your timeline
- Whether the additional cost of the Rubicon WGA service is more time/effort/cost effective than purchase and use of GenomePlex Kits.
Based on your requirements, Rubicon will quickly generate a project quote that contains all information about how your needs will be addressed, how to ship the samples to Rubicon, and contact information for all production matters. Once you approve of the project scope and quote, you will be asked for a Purchase Order or credit card number. When the Purchase Order or payment is received, and the samples are received by Rubicon, the project goes into production.
Input and output DNA is subject to QC procedures so that the customer receives a uniform product quality and concentration, regardless of the condition of the starting material, which eliminates critical variables for sequencing and genotyping. If input QC criteria of DNA quantity and concentration are met, Rubicon guarantees amplification to a specific amount of PCR-amplifiable DNA.
Typically, a Material Transfer Agreement is not necessary for an academic or institutional project. Proprietary samples sometimes require an MTA or other appropriate document, which Rubicon can provide.
Rubicon requires that you have IRB approval for your project, but does not need any evidence supporting that in our files. No patient data (coded or otherwise) should be sent with the samples.
Rubicon supports you with a direct contact in Commercial Operations, an electronic report that accompanies the return of amplified DNA, and continuing access to expert scientists and managers.
Customer Support and New Projects
To discuss existing projects, customers should contact Dr. Takao Kurihara, Associate Director of Commercial Operations, through our contact form or by phone at (734) 677-6894.
To discuss new projects, new and existing customers should contact Dr. John Langmore, VP Commercial Development, through our contact form or by phone at (734) 677-2797.
To discuss possible collaborations and partnerships, please contact Dr. John Langmore, VP Commercial Development, through our contact form or by phone at (734) 677-2797.